A Novel approach using O-CVP to treat paraneoplastic NMO spectrum disorder associated with follicular lymphoma.
| Autor: | Palmer DA; Department of Haematology, King's College London, London, UK david.palmer5@nhs.net., Dooley H; Department of Neurology, King's College London, London, UK., Pipis M; Department of Haematology, King's College London, London, UK., Patten P; Department of Haematology, King's College London, London, UK., Silber E; Department of Neurology, King's College London, London, UK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BMJ case reports [BMJ Case Rep] 2022 Nov 15; Vol. 15 (11). Date of Electronic Publication: 2022 Nov 15. |
| DOI: | 10.1136/bcr-2022-252822 |
| Abstrakt: | Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune neuroinflammatory disorder of the central nervous system that very rarely may be a paraneoplastic phenomenon. We describe the case of a woman with a longitudinally extensive transverse myelitis (LETM). We identified a previously undiagnosed, follicular lymphoma and she was treated with the immunochemotherapy regime (obinutuzumab, cyclophosphamide, vincristine and prednisolone; O-CVP) for paraneoplastic NMOSD. Following two cycles, there was almost complete radiological remission of the myelitis and the patient showed some improvement in her neurological function. This case illustrates the heterogeneous aetiology that LETM may have and that O-CVP may be used as therapeutic option in patients with NMOSD driven by follicular lymphoma. Competing Interests: Competing interests: HD, DAP, MP and ES have no competing interests. PP: the below are his competing interests. Specific funding: no specific funding regards this manuscript. Other funding: Research grants: Roche and Gilead. Payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events: Abbvie, Astra Zeneca, Gilead, Janssen, Novartis. Participation on a Data Safety Monitoring Board or Advisory Board: Abbvie, Beigene Employment: None. Personal financial interests: none. Patents: none. (© BMJ Publishing Group Limited 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|